**Core Concept**
Parkinsonism is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to reduced dopamine levels in the striatum. Treatment of Parkinsonism aims to increase dopamine levels or mimic its action in the brain.

**Why the Correct Answer is Right**
The primary goal of Parkinsonism treatment is to increase dopamine levels or stimulate dopamine receptors. Levodopa (A) is a precursor to dopamine, which is converted into dopamine in the brain, thereby increasing its levels. Dopamine agonists (B) directly stimulate dopamine receptors, mimicking the action of dopamine. MAO-B inhibitors (C) prevent the breakdown of dopamine, thereby increasing its levels. Amantadine (D) has a complex mechanism of action, but primarily it works as an NMDA receptor antagonist and also has some dopaminergic and anticholinergic effects.

**Why Each Wrong Option is Incorrect**
**Option A:** is actually true, as levodopa is a standard treatment for Parkinsonism.
**Option B:** is true, as dopamine agonists are commonly used in the treatment of Parkinsonism.
**Option C:** is true, as MAO-B inhibitors are used to prevent the breakdown of dopamine.
**Option D (assuming it's a statement):** This option is incorrect because amantadine's primary action is not directly related to increasing dopamine levels or stimulating dopamine receptors.

**Clinical Pearl / High-Yield Fact**
Amantadine also has a unique side effect of causing urinary incontinence due to its anticholinergic effects, which can be a significant issue in patients with Parkinsonism.

**Correct Answer: D.**